DBV Technologies SA (DBVT) Quote

DBVT 10Q March 4

DBVT new 52 week low

DBVT under $2

we are BACK!!

$AIHS WITHDRAWALS REGISTRATION https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170828693

1.6m shares short,better cover your nuts shorties

P&D but they are all over NASDAQ and it all depends if we can buy in low and dump for significant profits the same day. Risky? Of course but this is the new NASDAQ CASINO.

I got hooked yesterday on YGMZ
Hit 52-week high of $6.50 yesterday
Now it's trading at $1.55

I have a rule to never buy-into a China company.
I didn't follow my rule and I lost 35% yesterday.

i hope shorts get their nuts squeezed off,lol

lots of scanner buy signals>Strong Volume Gainers,Bullish MACD Crossovers,Parabolic SAR Buy Signals,Gap Ups,Filled Black Candles,Elder Bar Turned Green

Yup. The NASDAQ has many P&D's.

Thanks...
I think it's another pump PR.
But I'll keep this on the radar.

nice ss,big moves in past

lots of ppl with nut allergies,could see nice pop

DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial
December 23 2022 - 01:30AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook
Montrouge, France, December 23, 2022

DBV Technologies Announces FDA Has Lifted Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial

DBV expects to initiate patient screening in Q1 2023 with the last patient screened by 1H 2024 and topline results anticipated in 1H 2025
Company reiterates that cash on-hand is sufficient to fund operations through VITESSE topline data
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the Company’s VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety, Simplicity and Efficacy) Phase 3 clinical trial that will evaluate the modified Viaskin™ Peanut 250 µg patch (DBV712) in peanut-allergic children ages 4 to 7 years. The updated protocol will be submitted to study sites for subsequent Institutional Review Boards (IRB)/Ethics Committees (EC) approval.

In the Partial Clinical Hold (PCH) letter, the FDA requested changes to certain elements of the VITESSE protocol with the intent for the trial to support a Biologics License Application (BLA). The FDA communication contained four protocol modifications: the redefinition of the minimal daily wear time, the addition of a statistical test for the patch adhesion assessment, the reclassification of certain adverse events (AEs) to adverse events of special interest (AESIs) and an increase in the number of trial participants on active treatment.

Key design elements of VITESSE such as inclusion criteria, primary efficacy endpoint, responder criteria, efficacy assessment methodology and safety endpoints were not impacted by the PCH letter and have not changed.

“We are pleased that the FDA has lifted the partial clinical hold on the VITESSE study and anticipate initiating patient screening in Q1 2023,” said Daniel Tassé, Chief Executive Officer of DBV Technologies. “I am proud of our team for continuing to advance important pre-study activities these last several weeks so that we are prepared to act quickly to re-launch VITESSE following today’s announcement.”

Following receipt of the PCH letter, DBV and the FDA discussed how VITESSE protocol modifications could best support the Agency’s review of a potential BLA for Viaskin Peanut as a peanut allergy treatment.

In lifting the PCH, the FDA confirmed DBV satisfactorily addressed all clinical hold issues identified in the PCH letter. The FDA stated that DBV may proceed with VITESSE with the following changes included in the revised protocol:

The updated VITESSE Instructions for Use (IFU) will direct caregivers to apply one patch at approximately the same time each day, following removal of the previous day’s patch. The updated IFU now outlines that Viaskin Peanut 250 µg is to be worn for as close to a full day as possible (i.e., 24 hours) with a minimum daily wear time of 20 hours each day.
Patch adhesion will be assessed in VITESSE to affirm the modified Viaskin Peanut patch performs adequately, which aligns with existing regulatory requirements for patch-based therapies. In post-PCH discussions, DBV and the FDA agreed a statistical test of adhesion will be included in the VITESSE statistical analysis plan and further considered patch adhesion data collection and interpretation in the context of the novel nature of the Viaskin patch platform.
Four AEs will be classified as AESIs. These AEs – which include AEs leading to inhaled or systemic corticosteroid or epinephrine use, systemic allergic reactions, and Grade 4 local application site (skin) reactions – were collected and assessed in all previous Viaskin Peanut trials and included in the previous VITESSE protocol. Only the classification of these AEs has changed.
DBV plans to initiate a separate safety study in approximately 275 additional subjects, randomized 3:1 active versus placebo. The additional safety data generated by this six-month study will supplement the safety data generated by the VITESSE trial, resulting in a safety database comprised of approximately 600 children ages 4 to 7 years treated with Viaskin Peanut. The protocol design of the safety study will be submitted to the FDA and is expected to be similar to the REALISE (REAL Life Use and Safety of EPIT) safety study that DBV previously conducted with Viaskin Peanut in children ages 4 to 11 years.
The Company does not expect the additional safety study to have an impact on the Company’s cash runway guidance as DBV had included a provision for a possible supplemental safety trial in its cash runway assumptions. The Company reiterates that cash on-hand is sufficient to fund operations through VITESSE topline data.

“Following a very productive dialogue with the FDA, we have incorporated the Agency’s modifications to VITESSE into the study protocol and look forward to initiating patient treatments,” said Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies. “I am confident that the VITESSE study, when completed, will add to the growing body of evidence demonstrating the ability of our novel drug-device immunotherapy platform, Viaskin Peanut, to address significant unmet needs among peanut-allergic children and their families.”

DBV anticipates initiating VITESSE patient screening in the first quarter of 2023 with the last patient screened in 1H 2024 and topline results anticipated in 1H 2025.

About VITESSE
The VITESSE trial will enroll 600 subjects, randomized 2:1 active versus placebo. The study will involve approximately 80 trial sites across the United States, Canada, Australia and Europe. Dr. David Fleischer, Children’s Hospital Colorado, will act as the principal investigator.

The primary efficacy endpoint is the percentage of treatment responders in the active versus placebo arms at Month 12. The primary efficacy analysis includes the success criterion of a lower bound of the confidence interval of the difference in responder rates between active and placebo groups being greater than or equal to 15%.

A treatment responder is defined as either a subject with a baseline eliciting dose (ED) ≤30 mg who reaches an ED ≥300 mg of peanut protein at Month 12, or a subject with a baseline ED = 100 mg who reaches an ED ≥600 mg of peanut protein at Month 12. A double-blind, placebo-controlled food challenge (DBPCFC) will be administered at baseline and Month 12 to determine a subject’s ED at both timepoints.

During the screening period, subjects will undergo an initial visit with assessment for eligibility according to peanut skin prick test (SPT) and serum peanut IgE. Those meeting these criteria will proceed to a DBPCFC to confirm their peanut allergy and establish an entry peanut ED. The entry DBPCFC will be 1 mg peanut protein, and will escalate up to a highest single dose of 100 mg peanut protein. Subjects who react with an ED at or below the dose of 100 mg peanut protein are considered eligible. At Month 12, a post-treatment DBPCFC will be performed, with a starting dose of 3 mg peanut protein, escalating to a highest dose of 1,000 mg peanut protein according to the following schedule: 3, 10, 30, 100, 300, 600, 1,000 mg. Secondary efficacy endpoints include changes in Cumulative Reactive Dose, ED and severity of allergic reaction at Month 12 food challenge.

Damn. This was running to $4.00 -- until some assh### Insider dumped their shares.

Here we go - never really doubted it.

Rewards outweigh the risks here imo. DBVT recent news is very positive to me. The recent dump is from the "I want it NOW" and "can't wait" crowd. Patience will win the day.

I had to buy the news. From what I read they seem to have a path forward on a much needed treatment for peanut allergy peeps.

Didn't do a deep dive just dipped me toes in the water.

Will these upcoming conferences move the needle ? Perhaps further advancement of final stage(s) for approval ?

* * $DBVT Video Chart 01-15-2021 * *

Link to Video - click here to watch the technical chart video

Where are you sweet pee? CT

* * $DBVT Video Chart 11-03-2020 * *

Link to Video - click here to watch the technical chart video

* * $DBVT Video Chart 11-02-2020 * *

Link to Video - click here to watch the technical chart video

Nice call Boston kudos!

Significant dol vol pm here

About time we had some pm action jackson plays flowing again, glty as always GC!

Yep, she has life...

DBVT wakin' Golden

DBV Technologies Announces Filing and Validation of Marketing Autho...
Montrouge, France, November 2, 2020DBV Technologies Announces Filing and Validation of Marketing Authorization Application for Viaskin™ Peanut by European Medicines Agency DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: $DBVT ), a clinical-stage bioph...
https://finance.yahoo.com/news/dbv-technologies-announces-filing-validation-063000296.html

* * $DBVT Video Chart 01-30-2020 * *

Link to Video - click here to watch the technical chart video

GREAT news just out.

$DBVT 34 sec ago: DBV Tech up 23% after hours on positive long-term Viaskin data: DBV Technologies announces positive long-term results from the open-label extension study) of its Phase 3 clinical trial, PEPITES,.. newsfilter.io/articles/dbv-...

On the move tonight, since recenbt dilution stock moving from high 6s, to mid 10s tonight, news coming soon? Or just Baker Brothers buying in large creating momentum?

DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy
PRESS RELEASE GlobeNewswire
Aug. 7, 2019, 04:05 PM
Montrouge, France, August 7, 2019

DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Viaskin® Peanut for the treatment of peanut-allergic children ages 4 to 11 years. Viaskin Peanut is the Company’s lead product candidate based on epicutaneous immunotherapy (EPIT®). Viaskin is the Company’s proprietary, investigational platform that is designed to leverage the skin to activate the immune system and induce desensitization to allergens.

This submission addresses the additional data needed on manufacturing procedures and quality controls which were communicated by the FDA in December 2018, when DBV voluntarily withdrew its prior BLA submission for Viaskin Peanut. The FDA did not cite concerns related to the clinical module of the BLA for Viaskin Peanut in December 2018.

“This is an important milestone for DBV, as we are one step closer towards potentially bringing Viaskin Peanut to patients.I want to thank the team for their dedication in working to address the FDA’s findings over the past few months. Everyone at DBV is highly committed to potentially addressing the significant unmet medical need facing peanut-allergic patients,” stated Daniel Tassé, Chief Executive Officer of DBV Technologies. “We would also like to thank our investigators, clinical trial sites, as well as the children living with peanut allergy and their families for all of their help in the development of Viaskin Peanut. We look forward to working with the FDA throughout its review process.”

Viaskin Peanut received Breakthrough and Fast Track Designation from the FDA in 2015 and 2012, respectively. The BLA for Viaskin Peanut is supported by a global development program comprised of eight clinical trials including, two Phase I studies, four Phase II studies and two Phase III studies. The two double-blind placebo-controlled Phase III trials, PEPITES and REALISE, studied patients aged 4 to 11 years for 12 months and 6 months, respectively, and were included in the submission. Additionally, supportive long-term data from the Company’s open-label Phase II program were also included in the submission.

Bla submitted

Shyster

* * $DBVT Video Chart 07-05-2019 * *

Link to Video - click here to watch the technical chart video

JfC just go away

$DBVT daily chart: Nice pop today!

* * $DBVT Video Chart 04-04-2019 * *

Link to Video - click here to watch the technical chart video

Massive overreaction yes, still time to buy it up cheap, wont stay here for long.

Hope springs eternal......steady slow climb, re submission happening sooner than expected, 8.75 and climbing

Yes...the issues all surround manufacturing and QC issues. No concerns whatsoever with efficacy. Massive overreaction to the news.

anyone hear the cc? Earlier they said the snafu had to do with questions about the manufacturing,
That is not that hard a fix. Surprised it doesn't;t get up to 9 in a couple of days.

* * $DBVT Video Chart 12-20-18 * *

Link to Video - click here to watch the technical chart video

DBVT 1.1M Block Buy X $4.14 around @ 14:07:09 Expect a great recovery over 5+

Wow...getting crushed. Now at $4.60 from $14 yesterday.

They submitted and now have withdrawn submittal. $5.18 PM trading.

DBVT~~5.25 now,,62%% down

Ahha, and now, life returns. The curtain is not dropping yet.